APA (7th ed.) Citation

SE, N., G, M., L, G., M, R., G, F., R, C., . . . L, R. (2025). Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma. Journal of experimental & clinical cancer research : CR, 45(1), . https://doi.org/10.1186/s13046-025-03620-3

Chicago Style (17th ed.) Citation

SE, Navone, et al. "Revealing Erythropoietin Variant EV-3 as Novel Driving Force and Immunotherapeutic Target in Human Glioblastoma." Journal of Experimental & Clinical Cancer Research : CR 45, no. 1 (2025). https://doi.org/10.1186/s13046-025-03620-3.

MLA (9th ed.) Citation

SE, Navone, et al. "Revealing Erythropoietin Variant EV-3 as Novel Driving Force and Immunotherapeutic Target in Human Glioblastoma." Journal of Experimental & Clinical Cancer Research : CR, vol. 45, no. 1, 2025, https://doi.org/10.1186/s13046-025-03620-3.